Mukaddes Yılmaz

Mukaddes Yılmaz

Auto-generated profile, based on publicly available information

Mukaddes Yılmaz

Department of Medical Oncology, Sivas Cumhuriyet University, Sivas 58140, Turkey

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
RYRamazan Oğuz Yüceer
Ramazan Oğuz Yüceer
ŞKŞeyhmus KAYA
Şeyhmus KAYA
SBSema Nur Balcı
Sema Nur Balcı
HEHatice Reyhan Eğilmez
Hatice Reyhan Eğilmez
MYMukaddes Yılmaz
Mukaddes Yılmaz
EEEda Erdiş
Eda Erdiş
Background: Isocitrate dehydrogenase (IDH) wild-type (wt) glioblastoma is an aggressive malignancy associated with poor clinical outcomes, marked by high heterogeneity and resistance to treatment. This study aims to investigate the prognostic significance of B7-H3 expression in IDH wt glioblastoma and its potential association with clinical outcomes, including overall survival (OS) and progression-free survival (PFS). Additionally, the relationship between B7-H3 and PD-L1 expression was explored. Methods: A retrospective cohort of 86 IDH wt glioblastoma patients, all of whom underwent surgery, radiotherapy, and temozolomide treatment, was analyzed. B7-H3 expression was quantified using an immunoreactivity score (IRS), classifying samples as low (IRS ≤ 4) or high (IRS > 4). PD-L1 expression was evaluated based on tumor and immune cell staining, with >5% positivity indicating significant expression. Results: High B7-H3 expression was significantly associated with poorer OS and PFS. Co-expression of B7-H3 and PD-L1 was prevalent, particularly among younger male patients with unifocal tumors; however, PD-L1 expression did not show a significant correlation with clinical outcomes. Conclusions: B7-H3 appears to be a promising prognostic biomarker in IDH wt glioblastoma and may serve as a target for developing combination therapies, integrating B7-H3-targeting treatments with immune checkpoint inhibitors. Further prospective studies are necessary to validate these findings and to explore potential therapeutic strategies.

27 June 2025 in Medicine
Verified
Journal Article
Open access
RYRamazan Oğuz Yüceer
Ramazan Oğuz Yüceer
SASedanur Aydin
Sedanur Aydin
HÖHatice Özer
Hatice Özer
Asim Armagan AydinAsim Armagan Aydin
Asim Armagan Aydin
MYMukaddes Yilmaz
Mukaddes Yilmaz
TKTülay Koç
Tülay Koç
This study aimed to evaluate the prognostic and predictive significance of Claudin-6 and trophoblast cell surface antigen-2 (Trop-2) expression in serous ovarian carcinoma, assessing their influence on treatment efficacy and clinical outcomes. A retrospective cohort of 73 patients diagnosed with serous ovarian carcinoma was analyzed. All patients underwent standard cytoreductive surgery, with or without neoadjuvant or adjuvant chemotherapy. Immunohistochemistry was used to assess the expression levels of Claudin-6 and Trop-2. Survival outcomes were evaluated using Kaplan–Meier and Cox proportional hazards models, with overall survival (OS) as the primary endpoint. High Trop-2 expression was observed in 67.1% of the patients, while 46.6% exhibited high Claudin-6 expression. Both markers were more common in older, postmenopausal patients, those with larger tumors, and those with distant metastasis. However, no significant associations were found with clinical factors (P > .05). Survival analysis demonstrated that high Trop-2 and Claudin-6 expression were associated with shorter OS and progression-free survival (PFS). Patients with high Trop-2 expression exhibited a median OS of 38 months and PFS of 32 months, whereas those with low Trop-2 expression had a median OS of 62 months and PFS of 60 months (OS: P = .039, PFS: P = .020). Similarly, high Claudin-6 expression was associated with a median OS of 32 months and PFS of 21 months, compared to an OS of 60 months and PFS of 56 months in patients with low Claudin-6 expression (OS: P = .005, PFS: P = .003). Both univariate and multivariate analyses confirmed that advanced age, and high Trop-2, and high Claudin-6 expression were significant predictors of poor OS and PFS (P < .05). These findings underscore the prognostic significance of Claudin-6 and Trop-2 in ovarian cancer, with elevated expression correlating with poorer survival outcomes. These markers may serve as independent prognostic factors, and their targeting through antibody–drug conjugates offers a potential therapeutic strategy to improve survival outcomes and overcome treatment resistance.

29 September 2023 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
MYMukaddes Yılmaz
Mukaddes Yılmaz
EEEda Erdiş
Eda Erdiş
MUMahmut Uçar
Mahmut Uçar
BYBirsen Yücel
Birsen Yücel

24 July 2025 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
MUMahmut Uçar
Mahmut Uçar
MYMukaddes Yılmaz
Mukaddes Yılmaz
EEEda Erdiş
Eda Erdiş
BYBirsen Yücel
Birsen Yücel
Aim: In this study, we aimed to observe the prognostic significance of the pan‐immune‐inflammation value (PIV) score calculated at the time of diagnosis in patients with locally advanced rectal cancer, as well as its effect on treatment response, survival, and prognosis.Material and Method: This retrospective, single‐center observational study was designed to analyze patients with nonmetastatic (stages II–III) rectal cancer who received neoadjuvant treatment, categorized into two groups: PIV‐L (n = 67, 50%) and PIV‐H (n = 67, 50%). The median PIV score was used for cutoff determination. Survival analysis was applied. Univariate and multivariate Cox regression analyses were used to determine prognostic factors.Results: Preoperative clinical lymph node status (p = 0.011), liver metastasis (p = 0.028), carcinoembryonic antigen (CEA; p = 0.013), and cancer antigen 19.9 (CA19.9; p = 0.040) levels; pathological complete response (p = 0.035); tumor regression score (p = 0.030); postoperative lymph node status (p = 0.019); tumor deposits (p = 0.035); and budding (p = 0.043) were statistically different between the groups. The 5‐ and 10‐year overall survival (OS) rates were 77% versus 69% and 62% versus 38% in the PIV‐L and PIV‐H groups, respectively (p = 0.032). While the PIV score was prognostic for OS in univariate analysis (HR: 1.85, 95% CI: 1.04–3.31, p = 0.035), a result of insignificance was obtained in multivariate analysis (HR: 1.76, 95% CI: 0.98–3.01 p = 0.056). The 5‐ and 10‐year disease‐free survival (DFS) rates were 67% versus 54% and 56% versus 39% in the PIV‐L and PIV‐H groups, respectively, with the PIV‐H group showing a statistically significantly lower rate (p = 0.048). For DFS, the PIV score was found to be a statistically insignificant prognostic factor in univariate analysis (HR: 0.052, 95% CI: 0.99–2.86, p = 0.052) and recognized as an independent prognostic factor in multivariate analysis (HR: 1.87, 95% CI: 1.08–3.26, p = 0.026).Conclusion: A higher pretreatment PIV score was associated with poorer clinicopathological features, a worse treatment response, lower survival rates, and a poor prognosis for DFS.

1 September 2014 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
KSKaren-Lise Spindler
Karen-Lise Spindler
NPN. Pallisgaard
N. Pallisgaard
KSK. Skovgaard
K. Skovgaard
RARikke Andersen
Rikke Andersen
HHH. Hendel
H. Hendel
BVB. Vittrup
B. Vittrup
Aim: Small fractions of cell-free DNA (cfDNA) can be quantified from blood samples, is a mixture of DNA from malignant and normal cells, and can be used as a liquid biopsy to detect and quantify tumor specific hotspot mutations such as KRAS. We investigated the total cfDNA and the tumor specific circulating DNA with KRAS mutations in plasma from patients with metastatic colorectal cancer (mCRC) treated with third line cetuximab and irinotecan. Methods: Patients with histopathologically verified mCRC and adequate PS and organ function were included. All patients were resistant to 5-FU, oxaliplatin and irinotecan and treated with 3rd line irinotecan (180 mg/m2) and cetuximab (500 mg/m2) every second week in a prospective phase II study until disease progression or unacceptable toxicity. Plasma was obtained from a pre-treatment EDTA blood-sample, and the total cfDNA and plasma mutations were quantified by an in-house qPCR method. Quantitative levels of cfDNA were analyzed in relation to clinical data, and to tumor volume as estimated from pretreatment PET-CT. Results: Ninety-five patients were included. There was a significantly higher PFS and OS in patients with low levels of cfDNA, and decreasing median survival with increasing number of alleles. The OS in patients with total cfDNA in the lowest quartile was 17,0 months (95% CI 12.7 -19,8 months ) and 12,1 months (9.6–13,4 ), 9,2 months (6,9 -14,0) and 6,9 months (4,3–8,6) in the higher, respectively (p = 0.0001). The HR for patients with cfDNA levels above the 75% quartile indicated a strong detrimental effect on survival in this group of patients. The rate of tumor KRAS mutation (Exon 2) in this cohort was 34%, and a total of 30 patients had detectable plasma KRAS mutations. The levels of total cfDNA and tumor KRAS mutational alleles in the plasma were strongly correlated (spearman rank 0.88, p = 0.0001). Studies investigating the correlation of both total cfDNA and number of mutated alleles to tumor volume as estimated from PET-CT scans are on-going. Conclusions: The present study confirms a strong prognostic value of circulating DNA, and correlation between tumor and plasma KRAS. The results of relation to tumor volume will be presented at the meeting. Disclosure: All authors have declared no conflicts of interest.

1 January 2024 in Eurasian Journal of Medical Investigation
Verified
Journal Article
Closed access
PDF file
MYMukaddes Yılmaz
Mukaddes Yılmaz
Ejmi Eurasian Journal of Medical Investigation